Bristol-Myers Squibb Company (BMY)
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
Bristol-Myers Squibb Is Quietly Building Its Next Growth Cycle
Bristol-Myers Squibb Company sees its business tracking toward the upper end of full-year 2026 revenue and EPS guidance ranges. In my view, this primarily reflects strong demand for Breyanzi, Camzyos, and Reblozyl. Sales of this "trio" were $1.28 billion in Q1, up 42.2% year-over-year.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines.
Bristol-Myers Squibb Brings Anthropic's Claude to 30,000 of Its Staff
The deal helps solidify Anthropic's commitment to the life sciences sector as it targets more enterprise clients.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting
Bristol Myers Squibb NYSE: BMY used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while shareholders approved all management proposals and rejected a proposal to require an independent board chair.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Bristol-Myers Squibb Company (BMY) Q1 2026 Earnings Call Transcript
Bristol-Myers Squibb Company (BMY) Q1 2026 Earnings Call Transcript
